FDA rejects first nasal spray alternative to EpiPen for those with severe allergies
ARS Pharmaceuticals revealed late Tuesday evening that the FDA rejected what would have been the first epinephrine nasal spray.
The FDA requested another pharmacokinetic/pharmacodynamic study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
